Expansion Opportunity ApiJect just expanded manufacturing capacity in Apex, North Carolina, adding two BFS production lines and positioning as an FDA-registered 503B outsourcing facility. This creates a direct sales opening to supply essential generic injectable medicines on the FDA shortage list to US healthcare providers and pharmacy networks.

Strategic Partnerships Recent collaboration with Amneal Pharmaceuticals to expand sterile and BFS capabilities in the US indicates appetite for co-development or contract manufacturing arrangements. Target partners in generic injectables, oncology, or vaccines could leverage ApiJect’s single-use prefilled platform to reduce shortages and improve safety.

Public Benefit Focus Gates Foundation funding highlights a mission-driven push to make safe, single-use prefilled injectors affordable and accessible. This opens discussions with global health initiatives, NGOs, and government programs seeking cost-effective solutions for mass vaccination, emergency response, and low-resource settings.

Cost and Safety Levers The lightweight, break-resistant BFS single-dose injector eliminates glass, reduces syringe reuse risk, and supports low-cost, scalable deployments. Position ApiJect as a value-add for manufacturers and distributors aiming to mitigate shortages and enhance patient safety in high-demand therapeutic categories.

Technology and Compliance Readiness With an FDA-registered facility and a technology stack oriented toward scalable cloud and data management, ApiJect is equipped to meet regulatory, serialization, and quality assurance requirements. This enables sales conversations around compliant manufacturing, traceability, and rapid ramp-up for new injectable programs.